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Abstract
Background: Biliary cystic tumours (BCT) [biliary cystadenoma (BCA) and cystadenocarcinoma
(BCAC)] warrant complete resection. Simple liver cysts (SLC) require fenestration when symptomatic.
Distinguishing between BCT and atypical SLC with pre-operative imaging is not well studied.
Methods: All patients undergoing surgery for a pre-operative suspected SLC or BCT between 1992
and 2014 were included. Peri-operative data were retrospectively reviewed. A blind radiological review
of pre-operative imaging was performed.
Results: Ninety-four patients underwent fenestration (n = 54) or complete excision (n = 40). Final
pathology was SLC (n = 74), BCA (n = 15), BCAC (n = 2) and other primary malignancies (n = 3). A fro-
zen section (FS) was performed in 36 patients, impacting management in 10 (27.8%) by avoiding
(n = 1) or mandating a liver resection (n = 9). Frozen section results were always concordant with final
pathology. Upon blind review, a solitary lesion, suspicious intracystic component, septation and biliary
dilatation were associated with BCT (P < 0.05). Diagnostic sensitivity was high (87.5–100%) but speci-
ficity was poor (43.1–53.4%). The diagnostic value of imaging was most accurate when negative for
BCT (negative predictive value: 92.5–100%).
Conclusion: Radiological assessment of hepatic cysts is relatively inaccurate as SLC frequently pres-
ent with concerning features. In the absence of a strong suspicion of malignancy, fenestration and FS
should be considered prior to a complete resection.
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Introduction
Biliary cystic tumours (BCT), subdivided into biliary cystadeno-
ma (BCA) and cystadenocarcinoma (BCAC), represent less than
5% of all hepatic cystic lesions.1 The prevalence of liver cysts in
the general population is estimated at roughly 20%, and the inci-
dence is rising. This is probably related to the increased use of
abdominal cross-sectional imaging as a common diagnostic
tool.2,3 The principle differential diagnosis for BCT, once infec-
tious and metastatic liver lesions have been ruled out, is atypi-
cal-appearing simple liver cysts (SLC). To date, several clinical
and radiological ‘worrisome features’ have been reported but do
not provide reliable diagnostic differentiation between SLC and
BCT or between BCA and BCAC.4–9 The benefit of pre-operative
cyst fluid analysis is not used routinely, and its benefits are cur-
rently being debated.5,10 Accurately differentiating between BCT
and SLC is critical because the management differs according to
the diagnosis. SLC have no malignant potential and only require
surgical treatment when symptomatic; typically consisting of
laparoscopic fenestration. In contrast, BCT warrants a complete
resection owing to their malignant potential and their high
recurrence rate, ranging from 48.6% to 59.1% in cases of incom-
plete resection.9,11,12 Distinguishing between BCT and SLC with
pre-operative imaging remains challenging, and an inaccurate
pre-operative diagnosis can lead to inappropriate management
such as unnecessary liver resections for SLC or fenestrations for
BCT.
This study was presented as a long oral presentation at the Annual
Meeting of the AHPBA, 11-15 March 2015, Miami, Florida.
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The present study sought to evaluate the diagnostic accuracy
of pre-operative imaging of patients surgically evaluated for
SLC or BCT. Additionally, the impact of an intra-operative




A waiver of Health Insurance Portability and Accountability
Act authorization was obtained through Institutional Review
Board approval. Data from patients undergoing liver surgery at
our institution from January 1992 to January 2014 for any
pre-operatively suspected occurrence of SLC, BCA or BCAC
were collected from our prospectively maintained liver resec-
tion database. A pre-operative diagnosis of SLC was mainly
based on the exclusion of other pathological entities. Surgical
management was considered for symptomatic cysts or those
felt to be suspicious for BCT. The operative approach was
individualized according to the attending surgeon.
Clinical data
Clinical and demographic data were collected from the data-
base and supplemented by a review of the medical records.
The time interval from the first diagnosis of a liver cyst to sur-
gery and reasons for surgery were collected. Symptoms at the
time of surgery, as well as liver function tests and tumour
markers, were also recorded. A pre-operative diagnosis was
obtained from available notes from clinic and operative
reports. Data on the surgical approach, extent of surgery and
post-operative outcomes were collected. Surgery was classified
as follows: fenestration, enucleation or a liver resection. A liver
resection of three or more segments was defined as a major
resection. Intra-operative FS was performed at the discretion of
the treating surgeon and its impact on management was
recorded. Morbidity was recorded in the Memorial Sloan
Kettering Secondary Surgical Events program database using a
grading system consistent with the ‘Common Terminology
Criteria for Adverse Events Version 4.0’.13 Cyst recurrence at
last follow-up and management were documented.
Radiological review
Pre-operative imaging including ultrasound (US), computed
tomography (CT) and magnetic resonance imaging (MRI) was
performed within 3 months of surgery. These imaging studies
were performed at outside institutions and/or MSKCC and
were reviewed by two radiologists (S.G. and J.G.) blinded to all
clinical and pathological data. Reviewers excluded suboptimal
imaging studies, such as US without Doppler and CT or MRI
without intravenous contrast. Images were reviewed specifically
for the following features: size, solitary/multiple cysts thickness
of cyst walls, septations, intracystic component, intrahepatic
biliary dilatation and portal lymphadenopathy. Each radiologi-
cal feature, if present, was evaluated for findings potentially
consistent with BCT based on the following definitions. A cyst
wall was defined as suspicious if enhancing and thicker than
2 mm or contained mural nodules. Septations were deemed
suspicious if thicker than 3 mm or nodular.14 A worrisome
intra-cystic component was defined as any intra-cystic solid-
like component with features such as having a size larger than
10 mm with enhancement, calcifications or papillary projec-
tions. The intrahepatic bile duct was defined as dilated when
its diameter was greater than 2 mm. Lymph nodes were
deemed suspicious when measured larger than 10 mm in the
short axis. Based on all available imaging and using these crite-
ria, reviewers recorded their suspected diagnosis for each
patient. Examples of suspicious radiological features are pro-
vided in Fig. 1.
Final diagnosis
The pathological criteria for BCT were similar to the latest
World Health Organization definition.15 BCA was defined as a
(i) cystic neoplasm, (ii) without bile duct communication, (iii)
with cuboidal to columnar, variably mucin-producing epithe-
lium and (iv) mesenchymal ‘ovarian-like’ stroma. If any inva-
sive carcinoma was identified, the lesion was denoted as a
BCAC. SLC was defined as a cystic lesion lined by a thin wall
consisting of cuboidal epithelium with underlying fibrous
stroma. Agreement between the intra-operative FS diagnosis
and final pathology was assessed. The presence of dysplasia,
the margin status after enucleation or resection, and the
pathology of underlying non-cystic liver parenchyma were
recorded when available.
Statistical analysis
Categorical variables were summarized using percentages and
continuous variables were summarized using the median
(range). Characteristics of patients were compared using the
chi-square test for categorical variables and the Mann–Whitney
U-test for continuous variables to determine statistically signifi-
cant differences between SLC and BCT. The diagnostic accu-
racy of each reviewer was assessed using sensitivity and
specificity calculation. Inter-reviewer agreement was evaluated
using a Kappa–Cohen test.16,17 All P-values were based on
two-tailed statistical analysis and a P-value <0.05 was consid-
ered to indicate statistical significance. All analyses were per-
formed with SPSS software, version 22.0 for Windows (SPSS
Inc., Chicago, IL, USA).
Results
Descriptive data
From 1992 through to 2014, 3534 patients underwent liver sur-
gery at our institution, of which 94 (2.3%) were for one or
more hepatic cystic lesions pre-operatively diagnosed as SLC or
BCT. Baseline characteristics are listed in Table 1. Most
patients were female (83%) and about two-thirds were symp-
tomatic at presentation (64.9%). The median interval between
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diagnosis and surgery was 4 months (0–354). An initial conser-
vative approach with regular monitoring before surgery was
adopted in 24 patients. The reasons for such an approach was
a suspected SLC, for which a patient was initially asymptom-
atic (n = 22) or declining surgery (n = 2). In this group, the
median interval between diagnosis and surgery was 50 months
(range, 5–354). Pre-operative cyst fluid aspiration was per-
formed in 12 symptomatic patients and was combined with
concomitant tumour marker levels and cytology in 4 patients.
Cytology was positive in one patient who had a final diagnosis
of BCAC. On pre-operative imaging, the median tumour size
was 11.1 cm (range, 2–30). The cyst was noted to be located in
the right lobe (47.9%), left lobe (35.1%) or centrally (17%).
Operative data and outcomes
Intra-operative and pathology data
The pre-operative and final diagnoses are summarized in
Fig. 2. The overall discrepancy rate between pre-operative and
final diagnoses was 30.9% (n = 29). Eight patients (40%)
with BCT were pre-operatively misdiagnosed as SLC, whereas
21 patients with a final diagnosis of SLC (28%) were initially
misdiagnosed as BCT. Fifty-four patients underwent cyst fen-
estration, all for SLC. A complete resection consisted of enu-
cleation (n = 6) and a liver resection (n = 34), of which 20
patients had SLC. A major hepatectomy was performed on
13 patients (four with SLC). An extrahepatic resection was
carried out on three patients (a common bile duct resection
in one patient with BCA, a diaphragm resection and a trans-
verse colectomy in two patients with SLC). A laparoscopic
approach was used in 47 patients, mainly for cyst fenestration
(n = 44, 94%). Omentoplasty was combined with a fenestra-
tion in 13 cases, enucleation in five and a liver resection in
two. There was no mortality within 90 days. The major mor-
bidity rate was 6.4%. All patients who underwent a formal
liver resection had completely negative margins at final
pathology. In 34% of cases, SLC was reported as complicated
by an intracystic haemorrhage either at the time of fenestra-
tion or pathology.
Frozen section
Intra-operative FS was performed in 36 cases (38%). Twenty-
one (58%) of these 36 operations were performed laparoscopi-
cally. FS influenced surgical management in 10 patients (28%).
Nine patients were converted from fenestration to a complete
cyst resection after being diagnosed with BCT. In one patient,
a liver resection was avoided by diagnosing an SLC. In all
cases, an FS and final pathological diagnosis were concordant.
Outcomes
After a median follow-up of 39 months (range, 1–188), 13
patients (13.8%) experienced liver cyst recurrence. Eleven
patients with SLC treated with fenestration (20.3%) developed
a cyst recurrence, of which two were symptomatic at 82 and
188 months after surgery, respectively. One patient with BCAC
treated with a resection recurred in the liver after 8 months.




Figure 1 Suspicious cyst characteristics. (a) Magnetic resonance
imaging (MRI) T2 post contrast. Biliary cystadenoma with a
suspicious cyst wall (arrow) and suspicious septation (arrowhead).
(b) MRI T1. Biliary cystadenoma with a suspicious intracystic
component (arrow). (c) MRI T2 pre contrast. Simple liver cyst with a
suspicious intracystic component (arrow) and septation (arrowhead)
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the lung and the liver after 6 months. Both of these patients
with malignancy died within 12 months of surgery. No
patients with BCA (n = 15) died or experienced recurrence
after a median follow-up of 43.8 months (range, 1–180). Of
note, eight patients with BCA and one with BCAC had
intra-operative FS of a fenestration specimen before complete
resection. None of these patients has recurred after a median
follow-up of 16 months (range 12–83).
Table 1 Clinical and laboratory characteristics of patients with simple liver cysts and biliary cystic tumours
Total (n = 94) SLC (n = 74) BCT (n = 20) P
Demographics
Age 62 (23–86) 56 (23–74) 64 (35–86) 0.002
Female, n (%) 78 (83%) 61 (82.4%) 17 (85%) 1
BMI (n = 44) 27.4 (18–77) 27.7 (18–43) 26.8 (22–55) 0.9
Symptoms, n (%) 61 (64.9%) 50 (67.6%) 11 (55%) 0.313
Pain 52 (85.2%) 42 (84%) 10 (91%)
Weight Loss 3 (4.9%) 3 (6%) –
Jaundice 2 (3.3%) 1 (2%) 1 (9%)
Respiratory symptoms 4 (6.6%) 4 (8%) –
Pre-operative laboratory data
AST (U/l) (n = 78) 26.5 (9–135) 24 (9–135) 27 (17–41) 0.298
ALT (U/l) (n = 78) 26 (12–186) 24 (12–186) 31.5 (14–87) 0.224
Total Bilirubin (mg/dl) (n = 79) 0.5 (0.2–4.9) 0.5 (0.2–2.9) 0.6 (0.3–4.9) 0.83
CA 19-9 (U/ml) (n = 23) 26 (1–495) 20.8 (1–495) 47.5 (8–67) 0.236
CEA (ng/ml) (n = 30) 1.5 (0.1–72) 1.4 (0.1–7) 2.2 (1–72) 0.381
Bold variables are those which were significantly associated with BCT.







Initial FS, n = 33
Fenestration, n = 53
Enucleation, n = 4









Initial FS, n = 3:
Fenestration, n = 1
Enucleation, n = 2








Resection, n = 6
Figure 2 Management flow-chart of 94 patients with intrahepatic cystic lesions. BCA, biliary cystadenoma; BCAC, biliary
cystadenocarcinoma; FS, frozen section; ICC, intrahepatic cholangiocarcinoma; NET, neuroendocrine tumour; SLC, simple liver cyst
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Clinical and radiological characteristics associated
with BCT
Clinical and biological characteristics
A comparison between patients with SLC (n = 74) and with
BCT (n = 20) is shown in Table 1. Patients resected for BCT
were significantly younger (median 56 versus 64 years,
P = 0.002). Most patients with BCT and SLC were female
(85%) which was not statistically different between the groups.
Elevated serum liver enzymes or serum tumour markers levels
were not associated with BCT.
Radiological characteristics
Retrospective review of imaging reports
Reports of 204 imaging studies (80 US, 70 CT, 54 MRI) from
94 patients were reviewed. BCT was significantly associated
with a solitary cyst (n = 16; 80% versus n = 25; 33.8%;
P = 0.001). Similarly, BCT was associated with the presence of
an intracystic solid component (n = 5; 25% versus n = 6;
8.1%; P = 0.03) and tended to be associated with mural nod-
ules (n = 6; 30% versus n = 11; 14.9%; P = 0.09) and septa-
tions (n = 12; 60% versus n = 28; 37.8%; P = 0.07). Features
such as the presence or absence of biliary dilatation and portal
lymph nodes and estimations of wall thickness, septation
thickness and intracystic component size were not available in
every report and could not be included in the analysis.
Blinded imaging review
Twenty patients (SLC, n = 15; BCA, n = 4; BCAC, n = 1) who
had no available or suitable pre-operative imaging performed
within 3 months of surgery were excluded. Overall, 74 patients
(SLC, n = 57; BCA, n = 13; BCAC, n = 1, intrahepatic cholan-
giocarcinoma, n = 1, primary sarcoma, n = 1, neuroendocrine
tumour, n = 1) with 136 imaging studies were reviewed.
Twenty-six patients had one imaging modality (US, n = 7; CT,
n = 10; MRI, n = 9) and 34 had two pre-operative imaging
modalities (US+CT, n = 18; US+MRI, n = 13; CT+MRI, n = 3).
Fourteen patients underwent pre-operative US, CT and MRI.
Inter-reviewer agreement was moderate (Kappa–Cohen index =
0.49; 95%CI 0.29–0.69, P < 0.001). When considering the final
blinded radiological diagnosis, accuracy varied between review-
ers (Table 2). The sensitivity for BCT diagnosis ranged from
87.5% to 100%. All malignant cases (n = 4) were identified by
both reviewers. There was a trend towards an improved sensitiv-
ity with the number of imaging modalities, from 80% in patients
with one imaging modality to 100% in patients with two or three
imaging modalities. In contrast, specificity for BCT diagnosis
was low, ranging from 43.1 to 53.4%, resulting in a high-false
positive rate for BCT (36.5–44.6%). This finding was emphasized
by the low positive predictive value of imaging (29.8–37.2%)
and the high negative predictive value (92.5–100%) for BCT. Of
particular note, diagnostic accuracy was not influenced by the
study period (Table 3). In other words, imaging provided a reli-
able diagnostic result when negative for BCT but was inaccurate
when interpreted as positive or suggestive for BCT.
By combining all reviewed data, solitary lesion, suspicious
intracystic component and intrahepatic bile duct dilatation
were features significantly associated with BCT according to
both radiological reviews (Table 2). The presence of septations
was significantly associated with BCT according to one of the
reviewers.
Table 2 Radiological characteristics according to imaging review
Final diagnosis Reviewer 1 Reviewer 2
n = 74 SLC (n = 58) BCT (n = 16) P n = 74 SLC (n = 58) BCT (n = 16) P
Size, cm 11.3 (2–30) 10.7 (2–30) 9.8 (3.6–22) 0.641 11.8 (2–30) 10.9 (2–30) 9.9 (3.6–22) 0.441
Side
Right 38 (51.4%) 32 (55.2%) 6 (37.5%) 0.357 38 (51.4%) 32 (55.2%) 6 (37.5%) 0.357
Left 26 (35.1%) 18 (31%) 8 (50%) 26 (35.1%) 18 (31%) 8 (50%)
Central 10 (13.5%) 8 (13.8%) 2 (12.5%) 10 (13.5%) 8 (13.8%) 2 (12.5%)
Solitary 31 (41.9%) 20 (34.5%) 11 (68.8%) 0.021 31 (41.9%) 20 (34.5%) 11 (68.8%) 0.021
Suspicious wall 48 (64.9%) 33 (56.9%) 15 (93.8%) 0.007 60 (81.1%) 45 (77.6%) 15 (93.8%) 0.277
Septation 61 (82.4%) 45 (77.6%) 16 (100%) 0.058 59 (79.7%) 43 (74.1%) 16 (100%) 0.031
Suspicious septation 29 (39.2%) 21 (36.2%) 8 (50%) 0.317 40 (54.1%) 28 (14.3%) 12 (75%) 0.088
Suspicious intracystic component 26 (35.1%) 16 (27.6%) 10 (62.5%) 0.01 39 (52.7%) 26 (44.8%) 13 (81.3%) 0.012
IHBD 27 (36.5%) 17 (29.3%) 10 (62.5%) 0.015 22 (29.7%) 13 (22.4%) 9 (56.3%) 0.009
Suspicious LN 1 (1.4%) – 1 (6.3%) 0.216 1 (1.4%) – 1 (6.3%) 0.216
Radiology diagnosis SLC (n = 25) SLC (n = 2) SLC (n = 31) –
BCT (n = 33) BCT (n = 14) BCT (n = 27) BCT (n = 16)
Bold variables are those which were significantly associated with BCT.
BCT, biliary cystic tumour; IHBD, intrahepatic biliary dilatation; LN, lymph nodes; SLC, simple liver cyst.
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Discussion
Biliary cystic tumours are rare. Although SLC and BCT man-
agements are completely different, SLC can mimic BCT on
imaging. A reliable diagnosis is critical to ensure appropriate
management. The present study shows that characterization of
atypical intrahepatic cysts using imaging remains challenging.
Thus, surgeons treating pre-operatively suspected SLC or BCT
are faced with difficult management decisions while specific
guidance from radiological studies may be absent.
The diagnostic sensitivity of imaging for identifying BCT in
this study was high (87.5–100%), meaning that most BCT are
identified with pre-operative imaging. Such a high sensitivity is
as a result of suspicious imaging features that are present in
most BCT. Based on a blinded radiological review, we found
that features such as a solitary lesion, a suspicious intracystic
component, intrahepatic biliary dilatation and the presence of
septations were significantly associated with BCT. Hence, all
these features might be considered as suggestive of BCT. How-
ever, septations were also present in approximately three-quar-
ters of SLC and one-third of SLC was solitary or had a
suspicious intracystic component. This lack of specificity of pre-
operative imaging features for BCT accounted for the low posi-
tive predictive value of imaging (29.8–37.2%), which resulted in
a high false-positive rate for BCT. The patients with SLC mim-
icking BCT are at risk for being over treated with a resection,
theoretically exposing them to a higher risk of operative mor-
bidity. These findings document that pre-operative imaging
cannot reliably differentiate BCT and atypical SLC. When the
lesion was not suggestive for BCT, meaning a cystic lesion with-
out worrisome features, the diagnostic value of imaging was
most accurate (negative predictive value: 92.5–100%).
Frozen section was performed in 36 patients. Few publications
have reported cases where BCA was misinterpreted as SLC on
FS.18,19 In the current series, there was concordance between FS
diagnosis and a final diagnosis in all 36 cases. Notably, surgical
management was altered to a complete resection correctly in nine
patients initially planned for SLC fenestration. Given these results,
it is not surprising that 20 patients ultimately proven to have SLC
were initially suspected of having BCT and over treated with a
liver resection. This situation could have been safely obviated in
these patients with intra-operative FS. Intra-operative cyst fenes-
tration and sampling in patients who may have BCT is controver-
sial because of the theoretical risk of peritoneal spillage. In our
series, FS in patients with BCT appeared to be safe with no cases
of local or peritoneal recurrence (BCA, n = 8; BCAC, n = 1) after
a median follow-up of 18 months (range; 1–83). Taken all
together, these findings suggest that FS is a safe and accurate
approach for atypical cystic lesions characterization. While these
data are not definitive, it is still reasonable to avoid such a biopsy
in a lesion highly suspicious for an invasive malignancy.
Baseline characteristics such as demographics, clinical pre-
sentation and laboratory values were also explored. Patients
with BCT were significantly older than patients with SLC.
Patients with BCA (n = 15) were overwhelmingly women
(n = 14), middle-aged (median 50 years; range 23–69) and
53% were symptomatic at presentation (n = 8). However, 82%
of patients with SLC were also women. In our series, all
patients with pre-operatively suspected SLC went to surgery
because of symptoms at presentation but 67.6% of actual SLC
had symptoms at presentation. In contrast to previous reports,
symptoms at presentation were not associated with BCT.7
Regarding pre-operative laboratory values, neither serum liver
enzymes nor serum tumour markers levels such as CEA and
CA19-9 were associated with BCT. Few studies suggest that
cyst fluid analysis can help in distinguishing SLC from BCT,
but available data are conflicting and such analysis is currently
not warranted in clinical practice.5,10,20–23 In the present study,
pre-operative cyst fluid analysis was performed in only four
patients and could not be assessed for diagnostic utility.
Survival after liver surgery for BCT is usually prolonged. In the
most extensive series, 5-year overall survival was 84.2% in a
cohort of 221 patients with BCA and 27 with BCAC.9 In our cur-
rent series, patients with BCA (n = 15) were all alive at a median
follow-up of 18 months (range, 1–180). One patient was alive
without evidence of disease 83 months after a BCAC resection.
Another patient with BCAC experienced liver recurrence
6 months after a resection and died within 12 months of surgery.
Our findings have several limitations. First, this study was
retrospective over a 22-year time period. While imaging quality
has improved over time, diagnostic accuracy did not improve
when the analysis was restricted to the last 10 years. Second,
imaging studies were heterogeneous and not uniform for all
patients. However, a blinded, radiological review provided an
Table 3 Overtime diagnostic performances of imaging for biliary cystic tumour (BCT) based on radiological review in 74 patients




R1 R2 R1 R2 R1 R2 R1 R2
Whole period (1992–2014) (n = 74) 87.5% 100% 43.1% 53.4% 29.8% 37.2% 92.5% 100%
1992–2004 (n = 20) 100% 100% 41.2% 47% 23% 25% 100% 100%
2004–2014 (n = 54) 84.6% 100% 43.9% 56% 32.3% 41.9% 90% 100%
R1, Reviewer 1; R2, Reviewer 2.
HPB 2015, 17, 889–895 ª 2015 International Hepato-Pancreato-Biliary Association
894 HPB
unbiased assessment of images in a standardized fashion using
predefined criteria. Third, the presence of a mesenchymal ‘ovar-
ian-like’ stroma is an established feature of BCT as stated in the
latest WHO classification of tumours of the digestive system.15
Cysts composed of serous lining cells sitting on a basement mem-
brane without a mesenchymal stroma can indeed happen. How-
ever, this variant is virtually always benign. Although, few series
reported cystic lesions without such a stroma as BCT, we regard
them as benign simple biliary cysts.9,11,19 Additionally, the sample
size was small and very few patients had BCAC. This underscores
the relative rarity of BCT and the difficulty in studying these
tumours. Finally, most patients referred to our institution pre-
sented with complex and large cysts that may not be
representative of other practices. Furthermore, by definition, the
study only included patients who were selected to undergo a
resection. Given this selection bias, our results likely best apply to
patients presenting with atypical, simple liver cysts on imaging.
In conclusion, based on a blinded, radiological review, pre-
operative imaging cannot accurately differentiate atypical SLC
from BCT. Tissue sampling with cyst fenestration and FS is
safe and accurate. In the absence of features indicating invasive
malignancy, fenestration with tissue sampling and FS should
be considered an appropriate treatment strategy for any patient
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